Google
PHVS — PHARVARIS BV (Healthcare >> Biotechnology)
PHVS FAQ
What is PHVS's ROE?
PHARVARIS BV reports a Return on Equity (ROE) of -71.60%.
What is PHVS's dividend yield?
PHARVARIS BV offers a dividend yield of 0.00%.
What is PHVS's Deepscope Quality Score?
Deepscope rates PHVS's overall financial quality at 23 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy PHVS?
Deepscope's AI Timing Score for PHVS is 91 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does PHVS belong to?
PHARVARIS BV is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 31.09
Price
-0.54
(-1.71%)
Day Change
|
|
|---|
PHVS, the overall quality is not good ( Quality = 23) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Historical ROE is relatively low
Negative growth of ROE in the last year.
ROE is decreasing significantly
ROA is too relatively low compare to ROE
Growth of ROA was below our criteria in the last year.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
45% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 91 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 31.09 |
| PBV / Sector |
9.35 / 4.63
|
| Earning Per Share | -2.38 |
| PE / Sector |
N/A / 17.43
|
| PEG or PE/Growth / Sector |
N/A / 0.53
|
| Average 1M Daily Value |
11.62 M
GREAT
|
| Average 1W Daily Value |
14.21 M
GREAT
|
| Timing Factors |
|
71% |
| Financial Health |
|
41% |
| Ability to Make Profit |
|
37% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-06 09:09:06 |
| Symbol | PHVS |
| Name | PHARVARIS BV |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 69.88 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 2,210.30 / 8,857.28 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: Grafenauweg 8, Zug, Switzerland, 6300
Phone: 31 712036410
Website: https://pharvaris.com
Employees: 134
Sector: Healthcare >> Biotechnology
Description: Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
